Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Clairity, Inc.
United States
- Boston, Massachusetts
- 14/11/2025
- Series B
- $43,000,000
At Clairity, we believe that everyone should know their risk of breast cancer and have access to life-saving screening technology. Clairity's mammography-based deep learning platform is revolutionizing the screening process by improving accuracy, eliminating bias, cultivating trust, reducing the cost of care and saving lives.
- Industry Hospital & Health Care
- Website https://clairity.com/
- LinkedIn https://www.linkedin.com/company/clairity-inc/
Related People
Jeffrey R. LuberFounder
United States -
Greater Boston
I’m a four-time commercial CEO scaling category-first technologies at the intersection of AI and healthcare.
As CEO of Clairity, I’m leading commercialization of the first FDA-authorized platform for image-based breast cancer risk prediction, turning AI into actionable care pathways.
I’m also Chairman of Ibex (AI-powered pathology) and binx health (point-of-care sexual health), helping guide companies through growth, adoption, and global expansion.
My focus: moving bold science to real-world impact, fast.
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)